Analytical Data
-
Gene name
MIP-3 alpha/CCL20
- Application
-
Alternative Names
CCL20; CKb4; LARC; MIP3-A; SCYA20; ST38; Small Inducible Cytokine Subfamily A(Cys-Cys)Member 20; Beta-Chemokine Exodus-1; Liver And Activation-Regulated Chemokine
-
Species
Rat
-
Source
E. coli
-
Tag
N- His & GST
-
Purity
Greater than 85% as determined by SDS-PAGE.
-
Uniprot
P97884
-
Expression Region
Glu24~Lys95
-
Protein Length
Partial
-
Molecular Weight
40kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
MIP-3 alpha, also known as CCL20, is a chemokine that plays a crucial role in immune responses by attracting specific types of immune cells, notably CD4+ T lymphocytes and dendritic cells, to sites of inflammation. It is primarily produced by epithelial and endothelial cells in response to various stimuli, including infections and inflammatory cytokines. The significance of CCL20 in the pathogenesis of several diseases, particularly in autoimmune conditions, cancer, and chronic inflammatory disorders, has spurred considerable research interest. Understanding the mechanisms by which CCL20 mediates immune cell migration and its interactions with CCR6, its sole receptor, is vital for unraveling its role in both health and disease. To investigate these processes, researchers have developed recombinant CCL20 proteins, which facilitate the exploration of its biological functions, signaling pathways, and potential therapeutic applications. By utilizing recombinant technology, scientists aim to determine how CCL20 contributes to disease progression and assess its utility as a target for drug development, potentially leading to novel treatments for conditions characterized by dysregulated immune responses. The ongoing studies on MIP-3 alpha/CCL20 continue to enhance our understanding of immune system dynamics and open new avenues for intervention in disease management.
